Shares of Magellan Health (NASDAQ:MGLN) remained unaffected at $62.19 after the company reported Q1 results.
Earnings per share were up 187.50% year over year to $1.15, which beat the estimate of $0.72.
Revenue of $1,794,000,000 up by 3.10% year over year, which missed the estimate of $1,800,000,000.
Magellan Health hasn't issued any earnings guidance for the time being.
Magellan Health hasn't issued any revenue guidance for the time being.
How To Listen To The Conference Call
Date: May 11, 2020
Webcast URL: https://edge.media-server.com/mmc/p/iv2mmffn
Company's 52-week high was at $81.04
Company's 52-week low was at $30.60
Price action over last quarter: Up 5.39%
Magellan Health provides healthcare management services to health plans and other managed care organizations, employers, labor unions, United States government agencies, and third-party administrators. The firm operates in three segments: Healthcare, Pharmacy Management, and Corporate. The Healthcare business manages behavioral healthcare services and employee assistance program services, as well as specialty areas like diagnostic imaging. The Pharmacy Management segment includes pharmacy benefit management (PBM) services, pharmacy benefit administration for Medicaid and other government-sponsored programs, pharmaceutical dispensing operations, and clinical and formulary management programs. The Healthcare business generates the majority of revenue.